Iovance Biotherapeutics, Inc. IOVA
8.04 USD +0.30 (+3.88%)
At closeNov 6, 2026, 7:57 PM EST
8.05 +0.01 +0.07%
After hours · Nov 6, 7:57 PM ET
7.72 Day range 8.28
2.14 52-week range 14.86
- YTD
- +194.51%
- 1 year
- +248.05%
Analyst view
Consensus: buy
Buy
Price target (mean) 14.30 +77.9% upside
Now 8.04
- Target (low)
- 8.00
- Target (mean)
- 14.30
- Target (high)
- 20.00
Ratings (0m) 9 7 buy · 2 hold · 0 sell
- Strong buy2
- Buy5
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 10
- 2 months ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.08025 | -0.12 – -0.042 | -0.18 | +55.4% | 127.91M | +47.4% | 8 |
| Next quarter | -0.07714 | -0.14 – -0.04 | -0.19 | +59.4% | 134.05M | +87.7% | 7 |
| Current year | -0.451 | -0.50 – -0.408 | -1.09 | +58.6% | 414.20M | +57.2% | 8 |
| Next year | -0.19575 | -0.42 – -0.10 | -0.451 | +56.6% | 595.54M | +43.8% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Barclays | Maintained | Overweight | Overweight |
| Nov 6, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Nov 3, 2026 | UBS | Maintained | Neutral | Neutral |
| Oct 13, 2026 | Barclays | Maintained | Overweight | Overweight |
| Oct 8, 2026 | Baird | Maintained | Neutral | Neutral |
| Sep 30, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Sep 29, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 17, 2026 | Barclays | Maintained | Overweight | Overweight |
| Aug 25, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 20, 2026 | UBS | Maintained | Neutral | Neutral |
| Aug 18, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Aug 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Aug 7, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| May 7, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Apr 10, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Mar 5, 2026 | UBS | Maintained | Neutral | Neutral |
| Mar 3, 2026 | Citizens | Upgrade | Market Perform | Market Outperform |
| Feb 25, 2026 | Barclays | Maintained | Overweight | Overweight |
| Feb 25, 2026 | Citizens | Upgrade | Market Perform | Market Outperform |
| Dec 17, 2025 | Barclays | Maintained | Overweight | Overweight |
| Nov 24, 2025 | Barclays | Maintained | Overweight | Overweight |
| Nov 6, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Oct 29, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 19, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 8, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 8, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Jul 23, 2025 | Chardan Capital | Maintained | Buy | Buy |
| May 16, 2025 | UBS | Downgrade | Buy | Neutral |
| May 12, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| May 12, 2025 | Mizuho | Maintained | Outperform | Outperform |